Pa. High Court's Design Ruling Revives Fen-Phen Suit

Law360, Philadelphia (February 28, 2014, 6:19 PM EST) -- The Pennsylvania Supreme Court said Friday that its recent opinion concluding that pharmaceutical companies can be held liable for negligence in the design and marketing of drugs merited a lower court's reconsideration of a decision nixing a product liability suit against a Pfizer Inc. unit over the diet drug fen-phen.

The justices issued a one-page summary disposition ordering the Superior Court to reconsider the case in light of the new standard set for negligence claims against pharmaceutical companies by the Supreme Court in Lance v. Wyeth ruling in January.

The justices did not comment on the specifics of the case, but...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!